This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
High unmet need addressed with first new approved treatment in eighteen yearsMISSISSAUGA, ON,
August 6, 2014 /CNW/ - Health Canada has approved
® for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound [nab
®] paclitaxel) for first-line treatment of adult patients with metastatic pancreatic cancer. The approval is welcome news for Canadians who are diagnosed with metastatic pancreatic cancer, and represents the first approved treatment for this disease in nearly two decades.
The Health Canada approval was based on the results of MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial), an open-label, phase III, randomized, international study which was published in the
New England Journal of Medicine in October 2013. The MPACT study involved 861 chemotherapy-naïve patients with metastatic pancreatic cancer from 11 countries, including
Canada, and showed a statistically significant improvement in median overall survival with ABRAXANE plus gemcitabine compared to gemcitabine alone (8.5 vs. 6.7 months) (HR 0.72, P<0.0001); a 28% overall reduction in risk of death.
"This is a cancer where there are few effective treatments and the first-line approval of ABRAXANE in combination with gemcitabine represents an important advance," said. Dr.
Malcolm J. Moore, Program Head, Medical Oncology and Hematology and Director,
McCain Centre for Pancreatic Cancer at the Princess Margaret Cancer Centre, University Health Network in
Toronto and an investigator in the MPACT trial. "This approval will certainly have an impact on the way physicians manage this disease in the future. Pancreatic cancer is a tough one to deal with; patients are desperate and physicians are on the lookout for new advances. The addition of ABRAXANE to gemcitabine has demonstrated significant benefits in overall survival and this gives our patients hope."
"It's been quite some time since we've seen any type of treatment advance for pancreatic cancer making this news so important for patients. This will give patients the hope that is needed to continue to fight," said
Laurie Ellies, Co-founder, and Acting Executive Director of Pancreatic Cancer Canada. "Over the past decade, there has been a significant improvement in cancer survival rates. Sadly, the same cannot be said about pancreatic cancer. We're dealing with a deadly disease. For a person diagnosed with metastatic disease it can be a question of weeks. This year alone, we can expect an estimated 4,700 Canadians will be diagnosed with this disease. If anything, this number tells us that we are desperately in need of more research and treatments - patients are counting on it."
ABRAXANE is commercially available in
About Pancreatic CancerPancreatic cancer is the fourth-leading cause of cancer-related death in
2 The pancreas is composed of two main cell types: exocrine and endocrine. Adenocarcinoma is a sub-type of exocrine tumors and accounts for about 95% of cancers of the pancreas.
3 For all stages of pancreatic cancer combined, the five-year survival rate in
Canada is about 8%. For metastatic pancreatic cancer, the five-year survival is approximately 2% in